François graduated from the Swiss Federal Institute of Technology (ETHZ), in Zurich, and studied Biochemistry and Molecular Biology at the University of Zurich.
He received his Ph.D. from the Institute for Molecular Biology. He has spent over 20 years in the pharmaceutical industry.
During the early part of his career, he held various executive positions in R&D at Ciba-Geigy Pharma, wherehe headed the Molecular Genetics department in the newly formed Biotechnology division and at Sandoz Pharma, where he led the Gene and Cell Therapy business.
After joining Rhone Poulenc Rorer, where he has been head of Global Research, he became head of R&D at Aventis Pharma, France after the merger with Hoechst and lately CEO of Centelion, a biopharmaceutical affiliate company of Aventis Pharma.
He has been member of the board of directors of several privately owned biopharmaceutical companies in the US and in Europe and is currently member of the supervisory board of UniQure B.V..
François joined TxCell as CEO in January 2011 and became Chairman of the Board in November 2013.